Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
Saved in:
Main Authors: | Juraj Mokry (Author), Mark Giembycz (Author), Daniela Mokra (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
by: Marta Joskova, et al.
Published: (2020) -
Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): A Time for a New Player in the Treatment of Respiratory Diseases?
by: Daniela Mokra, et al.
Published: (2022) -
Advances in the Use of <i>N</i>-Acetylcysteine in Chronic Respiratory Diseases
by: Daniela Mokra, et al.
Published: (2023) -
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
by: Mark A Giembycz, et al.
Published: (2010) -
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
by: Heng Li, et al.
Published: (2018)